This launch of Epinephrine Injection multiple-dose Vial is eligible for 180 days of CGT exclusivity under section 505(j)(5)(B)(v) of the FD&C Act.
Glenmark’s Clindamycin Phosphate Foam, 1% is bioequivalent and therapeutically equivalent to Evoclin Foam, 1%, of Mylan Pharmaceuticals.
Novel illumination system with key components molded in Radel® PPSU for durability and repeated sterilization
According to IQVIATM sales data for the 12-month period ending November 2024, the Vitamin K1 Injectable Emulsion USP, 10 mg/mL market achieved annual sales of approximately $19.7 million
Jubilant Cadista will submit an appropriate action plan to the USFDA on these observations
The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market
According to IQVIATM sales data for the 12-month period ending October 2024, the Vimpat Oral Solution, 10 mg/mL market achieved annual sales of approximately $57.0 million
Glenmark's Travoprost Ophthalmic Solution USP, 0.004% is bioequivalent and therapeutically equivalent to the reference listed drug, Travatan Z Ophthalmic Solution USP, 0.004% of Sandoz
New research labs and process development services to enable next generation therapeutics
Univar Solutions' pharmaceutical ingredients portfolio will be strengthened by the addition of a broad range of cellulose ethers and other excipient solutions
Subscribe To Our Newsletter & Stay Updated
